Generally, the administration of osimertinib as a third generation EGFR‐TKI immediately after ICI treatment is not permitted because of a high incidence of ILD; however, as the first‐ or second‐generation EGFR‐TKI immediately after ICI is described to be feasible without increased frequency of ILD.5 First generation, especially erlotinib or second‐generation EGFR‐TKI, can be administered without severe hepatotoxicity, even immediately after ICI treatment. This evidence concerns the gene EGFR and interstitial lung disease.